Skip to main content
RT @EJoerns: Excited to share our recent work "IPAF: What the Rheumatologist Needs to Know."
@jeffsparks @UnaMakris @Dr

Elena Joerns EJoerns

4 years 3 months ago
Excited to share our recent work "IPAF: What the Rheumatologist Needs to Know." @jeffsparks @UnaMakris @DrDavidKarp @UTSW_LungLadies @UTSWRheum https://t.co/O0BsrRyHx8 https://t.co/R3lQMGFgUb
RT @kunalchandwar: 🔥Hot off the press🔥
🆕Our Comments on various GC protocols in @IJRheum
The changing paradigm

Kunal Chandwar kunalchandwar

4 years 3 months ago
🔥Hot off the press🔥 🆕Our Comments on various GC protocols in @IJRheum The changing paradigm of glucocorticoid therapy in antineutrophil cytoplasmic antibody-associated vasculitis https://t.co/4BjfkvPVAY https://t.co/gMXg7qQJWY
RT @drpnash: do we need another IL17a inhibitor? https://t.co/yf8cFNruzU

Peter Nash drpnash

4 years 3 months ago
do we need another IL17a inhibitor? https://t.co/yf8cFNruzU
RT @uptoTate: "Implementation (of guidelines) is key but remains the weakest part of the process" Dr. @DanielAletaha #EU

Dr. Rachel Tate uptoTate

4 years 3 months ago
"Implementation (of guidelines) is key but remains the weakest part of the process" Dr. @DanielAletaha #EULAR2022 @RheumNow https://t.co/9ULIAA7dvg
RT @RheumTweeter: Easy clinical tool for predicting lymphoma development at the time of #Sjogrens syndrome #EULAR2022 ht

Christian Ammitzbøll RheumTweeter

4 years 3 months ago
Easy clinical tool for predicting lymphoma development at the time of #Sjogrens syndrome #EULAR2022 https://t.co/tQ6B0iVRnb
RT @RichardPAConway: Dr Buch. ORAL Surveillance. MACE, VTE, Malignancy all more common in those with high (>20%) base

Richard Conway RichardPAConway

4 years 3 months ago
Dr Buch. ORAL Surveillance. MACE, VTE, Malignancy all more common in those with high (>20%) baseline CV risk or history CAD. HRs 1-2 for most but for VTE and high baseline CV risk, HR 6-11! @RheumNow #EULAR2022 POS0237 https://t.co/9DI4KotyOp
RT @ARD_BMJ: Dr Elena Nikiphorou explaining how the Western diet can bring on and worsen inflammation joint disease symp

ARD & RMD Open ARD_BMJ

4 years 3 months ago
Dr Elena Nikiphorou explaining how the Western diet can bring on and worsen inflammation joint disease symptoms. We should look to include more Omega 3 than Omega 6 in our diets #EULAR2022 PB https://t.co/nIKOSDPURU
RT @AshimaMakol: A very comprehensive overview of progress in the understanding of #IIM pathogenetic mechanisms outlinin

Ashima Makol MD AshimaMakol

4 years 3 months ago
A very comprehensive overview of progress in the understanding of #IIM pathogenetic mechanisms outlining the role of 👉 Type 1 INF pathway 👉 Vasculopathy 👉 NETs 👉 Mitochondrial Dysfunction #EULAR2022 Dr. Lisa Rider https://t.co/BXbXlYTHYM
RT @RichardPAConway: van Dijk et al. MTP squeeze positivity is caused by both MTP synovitis (OR 3.2 (1.4–7.2) and inte

Richard Conway RichardPAConway

4 years 3 months ago
van Dijk et al. MTP squeeze positivity is caused by both MTP synovitis (OR 3.2 (1.4–7.2) and intermetatarsal bursitis (OR 3.9 (1.7–8.8)). If + MTP squeeze - 10% synovitis, 15% IMB and 13% both @RheumNow #EULAR2022 OP0290 https://t.co/eVSU4i8gBK
RT @drdavidliew: Robert Landewe isn't lying down.

"I am chatting to my artificial intelligence doctor in the United Sta

David Liew drdavidliew

4 years 3 months ago
Robert Landewe isn't lying down. "I am chatting to my artificial intelligence doctor in the United States. I am asking him why I had a headache in the last talk" He worries telehealth reverts to box checking, & we're not ready to drop thinking from medicine #EULAR2022 @RheumNow https://t.co/ApBS4T4Wpc
RT @ARD_BMJ: CAR-T cell treatment of refractory systemic #lupus
Biological results
#SLE
#EULAR2022

>CR https://t.co/

ARD & RMD Open ARD_BMJ

4 years 3 months ago
CAR-T cell treatment of refractory systemic #lupus Biological results #SLE #EULAR2022 >CR https://t.co/JK4lsWcn2c
RT @AurelieRheumo: Remission in PsA

❗️According to DAS28-CRP
*22% never achieve a state of remission
*< than ha

Aurelie Najm AurelieRheumo

4 years 3 months ago
Remission in PsA ❗️According to DAS28-CRP *22% never achieve a state of remission *< than half achieved at least stage of SR ❗️According to DAPSA28 *73% never achieve a state of remission Are we that bad? Or do we need different measures? Or both? @RheumNow OP0262 #EULAR2022 https://t.co/6aeNW17VWg
RT @AurelieRheumo: 📈 Machine learning driven phenotyping in PsA

4 clusters of pts treated w/ Guselkumab identified

Aurelie Najm AurelieRheumo

4 years 3 months ago
📈 Machine learning driven phenotyping in PsA 4 clusters of pts treated w/ Guselkumab identified 📊 1 cluster w/ higher BL disease burden associated w/ worst response As fancy as it gets, not sure how to implement these in practice 🧐 @RheumNow #EULAR2022 OP0259 https://t.co/75X4ZqeEQJ
RT @Janetbirdope: @RichardPAConway @CatherineL_Hill @rheum_cat @RheumNow @KDAO2011 @uptoTate @AurelieRheumo Hello. @Rheu

Janet Pope Janetbirdope

4 years 3 months ago
@RichardPAConway @CatherineL_Hill @rheum_cat @RheumNow @KDAO2011 @uptoTate @AurelieRheumo Hello. @RheumNow reports @eular_org #EULAR2022 and teaches many. I learn as a tweeter. Way to go for all people tweeter this meeting. https://t.co/W3DuoVdfby
RT @Yuz6Yusof: When Tweeps meet IRL #EULAR2022 #queensjubilee2022 @YelizPrior @DrMiniDey @chriswincup https://t.co/cnTFw

Md Yuzaiful Md Yusof Yuz6Yusof

4 years 3 months ago
When Tweeps meet IRL #EULAR2022 #queensjubilee2022 @YelizPrior @DrMiniDey @chriswincup https://t.co/cnTFw2jjVd
×